Premature Ovarian Failure Treatments

Find Premature Ovarian Failure Treatments

Generic Name

Fenofibrate

Brand Names

Lipofen, Tricor

FDA approval date: May 13, 2005

Classification: Peroxisome Proliferator Receptor alpha Agonist

Form: Tablet, Capsule

What is Lipofen (Fenofibrate)?

LIPOFEN is a peroxisome proliferator-activated receptor alpha agonist indicated as an adjunct to diet: To reduce elevated LDL-C, total-c, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

Window of Opportunity Trial of Fenofibrate in Patients With High-grade Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma

Enrollment Status: Recruiting

Publish Date: July 27, 2026

Intervention Type: Procedure, Drug, Radiation

Study Phase: Phase 1

Summary: Normally, p53 helps prevent tumors from forming in the body. Early studies have shown that Fenofibrate, a cholesterol-lowering drug, can restore normal function to p53 and can change the metabolism of HPV-positive tumors in a way that stops the growth of tumors. The purpose of this study is to understand how Fenofibrate can be used to treat HPV-positive cervical cancers and cervical dysplasia. Res...

Effect of Bacillus Subtilis and Enterococcus Faecium Combination Therapy Combined With Conventional Lipid-Lowering Treatment on Triglyceride Levels in Patients With Hypertriglyceridemic Acute Pancreatitis: A Prospective Randomized Controlled Trial

Enrollment Status: Recruiting

Publish Date: July 22, 2026

Intervention Type: Drug

Study Phase: Phase 4

Background: Hypertriglyceridemia-associated acute pancreatitis (HTG-AP) has become the second most common cause of acute pancreatitis in China, accounting for up to 42.4% of cases, with high recurrence rates and substantial disease burden. Disease severity and recurrence risk are potentially linked to triglyceride (TG) levels. Current lipid-lowering strategies have limitations in efficacy, onset speed, or saf...

Peroxisome Proliferator-Activated Receptor Agonists to Prevent Primary Sclerosing Cholangitis Recurrence After Liver Transplantation

Enrollment Status: Recruiting

Publish Date: July 17, 2026

Intervention Type: Diagnostic test, Drug

Study Phase: Phase 2

Summary: This study aims to determine the efficacy of 36 months once-daily fenofibrate in preventing clinically-detectable recurrence of primary sclerosing cholangitis after liver transplantation, compared with a historical control cohort that was not treated with

View All Clinical Trials